York biotech firm Aptamer Group revenue rises 28 per cent

Summarised from 2 outlets · Updated 13 Oct, 11:02 · Archive

York-based Aptamer Group reported a 28 per cent increase in revenue to £1.5 million for the year to June 2026.

Aptamer Group, a York-based life sciences firm, reported a 28 per cent increase in revenue to £1.5 million for the year to June 30, 2026, up from £1.2 million the previous year. The company, which develops synthetic binders known as Optimers, improved its cash position to £4.4 million, supported by a £4.1 million equity raise in April 2026.

Chief executive Arron Tolley said the company had moved from proving its technology to proving its business model. He highlighted two royalty-bearing licences now signed, repeat orders from multiple top 20 pharmaceutical companies, and the company's first entry into the radioligand therapy market. Tolley added that the company had expanded manufacturing capacity to support partners at commercial scale and was building a therapeutic pipeline spanning RNAi delivery to multiple diseases including fibrosis and kidney, along with radiopharmaceuticals.

Adjusted EBITDA loss was £2.3 million, in line with the previous year's £2.2 million, while administration expenses rose to £3.2 million from £2.9 million. The board said the current cash balance provides a financial runway into 2028, excluding any additional licensing income.

How it is being reported

• York biotech firm's revenues rise 28 per cent to £1.5m as deals are struckA year of strong growth has seen revenue rise and key commercial milestones reached.The Press (York) · 13 Oct, 09:26
• York biotech firm's revenues rise 28 per cent to £1.5m as deals are struckA year of strong growth has seen revenue rise and key commercial milestones reached.Gazette & Herald (Malton) · 13 Oct, 09:26

In this story: Aptamer Group · York · Arron Tolley

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem